Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01521117 · ClinicalTrials.gov registry record · Phase 4
The Effect of Donepezil on Gait and Balance in Parkinson's Disease
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT01521117 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 21 participants.
The verdict
NCT01521117, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study involves Parkinson's disease (PD). Symptoms include slow movement, tremor, and muscle rigidity. Current medications for the treatment of PD do not improve gait and balance difficulties in individuals with PD. Donepezil (study drug) has been found to reduce falls in individuals with PD. The mechanism in which this reduction of falls occurs is unclear. The investigators study will look at what aspects of gait and balance are improved by the study drug. The study drug is not approved to treat PD in the United States or other countries because we do not know enough about it.
Interventions
- DRUG Placebo
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01521117
The ClinicalTrials.gov registry entry for NCT01521117 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01521117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01521117 about?
NCT01521117 is a clinical study titled "The Effect of Donepezil on Gait and Balance in Parkinson's Disease". This study involves Parkinson's disease (PD). Symptoms include slow movement, tremor, and muscle rigidity. Current medications for the treatment of PD do not improve gait and balance difficulties in individuals with PD. Donepezil (study drug) has been found to reduce falls in individuals with PD. Th...
What is the current status of trial NCT01521117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2011-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01521117?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT01521117?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.